Enanta Pharmaceuticals, Inc. (FRA:9EP)

Enanta Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is October - September.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 23, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Market Capitalization	333	218	197	222	1,096	991
Market Cap Growth	220.53%	10.81%	-11.43%	-79.73%	10.64%	26.62%
Enterprise Value	291	221	155	69	825	676
Last Close Price	11.30	10.00	9.05	10.40	52.50	49.00
PS Ratio	5.83	3.92	3.25	2.97	12.48	11.83
PB Ratio	3.09	3.95	1.70	1.09	3.35	2.88
P/TBV Ratio	3.09	3.95	1.70	1.09	3.35	2.88
EV/Sales Ratio	5.13	3.96	2.56	0.93	9.39	8.08
EV/FCF Ratio	-18.53	-	-	-	-	-
Debt / Equity Ratio	1.53	3.11	1.76	1.03	0.08	0.02
Net Debt / Equity Ratio	-0.38	0.19	-0.17	-0.68	-0.78	-0.86
Net Debt / EBITDA Ratio	0.72	-0.15	0.19	1.09	2.08	3.25
Net Debt / FCF Ratio	2.64	-0.38	0.23	1.31	2.90	4.89
Asset Turnover	0.20	0.20	0.16	0.19	0.21	0.21
Quick Ratio	4.35	4.03	4.99	6.52	10.00	8.43
Current Ratio	4.44	4.21	5.21	6.73	10.45	8.82
Return on Equity (ROE)	-60.01%	-84.63%	-67.16%	-49.74%	-33.78%	-18.48%
Return on Assets (ROA)	-13.47%	-16.23%	-18.13%	-20.47%	-19.01%	-14.81%
Return on Invested Capital (ROIC)	-69.31%	-92.97%	-138.32%	-163.29%	-94.88%	-91.02%
Return on Capital Employed (ROCE)	-25.70%	-36.80%	-38.10%	-34.30%	-35.80%	-27.20%
Earnings Yield	-18.31%	-32.00%	-52.86%	-56.90%	-11.33%	-6.88%
FCF Yield	-4.73%	-12.57%	-44.06%	-47.71%	-8.08%	-6.16%
Buyback Yield / Dilution	-9.53%	-0.85%	-0.90%	-1.78%	-2.14%	-1.16%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.